Zinc binding groups for histone deacetylase inhibitors

被引：183

作者：

Zhang, Lei ^{[1
]}

Zhang, Jian ^{[1
]}

Jiang, Qixiao ^{[2
]}

Zhang, Li ^{[2
]}

Song, Weiguo ^{[1
]}

机构：

[1] Weifang Med Univ, Sch Pharm, Dept Med Chem, Weifang, Shandong, Peoples R China

[2] Qingdao Univ, Sch Pharm, Qingdao, Shandong, Peoples R China

来源：

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY | 2018年 / 33卷 / 01期

关键词：

Histone deacetylase inhibitor; zinc binding group; anti-tumour; selectivity; drug design; PHASE-I; CARDIAC-HYPERTROPHY; VALPROIC ACID; ORAL CI-994; POTENT; COMBINATION; IDENTIFICATION; MGCD0103; CANCER; ST7612AA1;

D O I：

10.1080/14756366.2017.1417274

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Zinc binding groups (ZBGs) play a crucial role in targeting histone deacetylase inhibitors (HDACIs) to the active site of histone deacetylases (HDACs), thus determining the potency of HDACIs. Due to the high affinity to the zinc ion, hydroxamic acid is the most commonly used ZBG in the structure of HDACs. An alternative ZBG is benzamide group, which features excellent inhibitory selectivity for class I HDACs. Various ZBGs have been designed and tested to improve the activity and selectivity of HDACIs, and to overcome the pharmacokinetic limitations of current HDACIs. Herein, different kinds of ZBGs are reviewed and their features have been discussed for further design of HDACIs.

引用

页码：714 / 721

页数：8

共 69 条

[1] Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model [J].

Attenni, Barbara ;

Ontoria, Jesus M. ;

Cruz, Jonathan C. ;

Rowley, Michael ;

Schultz-Fademrecht, Carsten ;

Steinkuehler, Christian ;

Jones, Philip .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (11) :3081-3084

[2] COMPARISON BETWEEN THE EFFECT OF BUTYRIC-ACID AND ITS PRODRUG PIVALOYLOXYMETHYLBUTYRATE ON HISTONES HYPERACETYLATION IN AN HL-60 LEUKEMIC-CELL LINE [J].

AVIRAM, A ;

ZIMRAH, Y ;

SHAKLAI, M ;

NUDELMAN, A ;

REPHAELI, A .

INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (06) :906-909

[3]

Battistuzzi Gianfranco, 2016, Curr Bioact Compd, V12, P282

[4] Targeting Histone Deacetylases in Diseases: Where Are We? [J].

Benedetti, Rosaria ;

Conte, Mariarosaria ;

Altucci, Lucia .

ANTIOXIDANTS & REDOX SIGNALING, 2015, 23 (01) :99-126

[5] Genomewide studies of histone deacetylase function in yeast [J].

Bernstein, BE ;

Tong, JK ;

Schreiber, SL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (25) :13708-13713

[6] Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents [J].

Bian, Jiang ;

Zhang, Lihui ;

Han, Yantao ;

Wang, Chunbo ;

Zhang, Lei .

CURRENT MEDICINAL CHEMISTRY, 2015, 22 (17) :2065-2074

[7] Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia [J].

Blum, Kristie A. ;

Advani, Anjani ;

Fernandez, Louis ;

Van Der Jagt, Richard ;

Brandwein, Joseph ;

Kambhampati, Suman ;

Kassis, Jeannine ;

Davis, Melanie ;

Bonfils, Claire ;

Dubay, Marja ;

Dumouchel, Julie ;

Drouin, Michel ;

Lucas, David M. ;

Martell, Robert E. ;

Byrd, John C. .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) :507-514

[8] Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay [J].

Bonfils, Claire ;

Kalita, Ann ;

Dubay, Marja ;

Siu, Lillian L. ;

Carducci, Michael A. ;

Reid, Gregory ;

Martell, Robert E. ;

Besterman, Jeffrey M. ;

Li, Zuomei .

CLINICAL CANCER RESEARCH, 2008, 14 (11) :3441-3449

[9] HDAC8: a multifaceted target for therapeutic interventions [J].

Chakrabarti, Alokta ;

Oehme, Ina ;

Witt, Olaf ;

Oliveira, Guilherme ;

Sippl, Wolfgang ;

Romier, Christophe ;

Pierce, Raymond J. ;

Jung, Manfred .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) :481-492

[10] Histone deacetylase inhibitors as cancer therapeutics [J].

Clawson, Gary A. .

ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (15)

← 1 2 3 4 5 6 7 →